Spots Global Cancer Trial Database for hematopoietic cell transplantation recipient
Every month we try and update this database with for hematopoietic cell transplantation recipient cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation | NCT06266182 | Hematopoietic C... Acceptance and ... | Acceptance and ... Education | 18 Years - | University of Social Sciences and Humanities, Warsaw | |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | NCT00736749 | Hematopoietic C... Leukemia Solid Tumor | Assessment of T... Questionnaire A... | - | Children's Oncology Group | |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03531281 | Hematopoietic a... Hematopoietic C... | Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra... | 12 Years - 60 Years | City of Hope Medical Center | |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | NCT00736749 | Hematopoietic C... Leukemia Solid Tumor | Assessment of T... Questionnaire A... | - | Children's Oncology Group | |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | NCT03195010 | Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... B-Cell Non-Hodg... Chronic Lymphoc... Chronic Myeloge... Hematologic and... Hematopoietic C... Myelodysplastic... Primary Myelofi... Secondary Myelo... T-Cell Non-Hodg... Thrombocytopeni... Venous Thromboe... | Platelet Transf... Platelet Transf... | 18 Years - | Fred Hutchinson Cancer Center | |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03531281 | Hematopoietic a... Hematopoietic C... | Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra... | 12 Years - 60 Years | City of Hope Medical Center | |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03494569 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Hematopoietic C... Minimal Residua... Myelodysplastic... Secondary Acute... | Fludarabine Laboratory Biom... Melphalan Total Marrow Ir... | 12 Years - | City of Hope Medical Center | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03438344 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Bone Marrow Tra... Chronic Lymphoc... Chronic Phase C... Hematopoietic C... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Multi-antigen C... Laboratory Biom... Placebo | 18 Years - | City of Hope Medical Center | |
| Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders | NCT03626285 | Benign Neoplasm Bone Marrow Tra... Hematopoietic C... Malignant Neopl... | Bone Marrow Tra... CliniMACS CD34 ... Peripheral Bloo... | - 70 Years | OHSU Knight Cancer Institute | |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01718743 | Hematopoietic C... Plasma Cell Mye... | Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT03583424 | Hematopoietic C... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Tran... | Carmustine Cytarabine Etoposide Hematopoietic C... Melphalan Venetoclax | 19 Years - | Ohio State University Comprehensive Cancer Center | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03438344 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Bone Marrow Tra... Chronic Lymphoc... Chronic Phase C... Hematopoietic C... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Multi-antigen C... Laboratory Biom... Placebo | 18 Years - | City of Hope Medical Center | |
| Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT02420860 | Hematopoietic C... Plasma Cell Mye... | Elotuzumab Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | NCT03328936 | Hematopoietic C... Recurrent Plasm... Refractory Plas... | Laboratory Biom... Melphalan Hydro... Melphalan Hydro... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01718743 | Hematopoietic C... Plasma Cell Mye... | Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
